###begin article-title 0
Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies
###end article-title 0
###begin p 1
Neuronal pentraxin II (NPTX2) is the most highly upregulated gene in the Parkinsonian substantia nigra based on our whole genome expression profiling results. We show here that it is a novel component of Lewy bodies and Lewy neurites in sporadic Parkinson's disease (PD). NPTX2 is also known as the neuronal activity-regulated protein (Narp), which is secreted and involved in long-term neuronal plasticity. Narp further regulates AMPA receptors which have been found to mediate highly selective non-apoptotic cell death of dopaminergic neurons. NPTX2/Narp is found in close association with alpha-synuclein aggregates in both substantia nigra and cerebral cortex in PD but unlike alpha-synuclein gene expression, which is down-regulated in the Parkinsonian nigra, NPTX2 could represent a driver of the disease process. In view of its profound (>800%) upregulation and its established role in synaptic plasticity as well as dopaminergic nerve cell death, NPTX2 is a very interesting novel player which is likely to be involved in the pathway dysregulation which underlies PD.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s00401-007-0309-3) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Keywords
###end title 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 503 505 503 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 956 957 956 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 1137 1138 1137 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 667 670 <span type="species:ncbi:10116">rat</span>
Neuronal pentraxins constitute a family of proteins that are homologous to C-reactive and acute-phase proteins in the immune system and are thought to be involved in activity-dependent synaptic plasticity [1, 11, 32]. The neuronal pentraxins (NPTX1, NPTX2) and the neuronal pentraxin receptor were identified as synaptic proteins that bind to affinity columns of the snake venom toxin, taipoxin which presynaptically blocks neurotransmission, and the luminal calcium-binding protein TCBP49 [15]. NPTX2 [14] is also known as neuronal activity-regulated pentraxin (Narp), which was first identified as an immediate early gene responding to the induction of seizures in rat hippocampus [31]. The expression of this protein is regulated by synaptic activity and it induces the formation of new excitatory synapses and the regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor clustering at established synapses [7, 22, 23]. Importantly, dopaminergic neurons are selectively susceptible to excitotoxicity mediated via AMPA receptor activation with the resulting cell death being non-apoptotic [5].
###end p 6
###begin p 7
###xml 208 209 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
A second line of research that makes NPTX2 a highly interesting gene in the context of Parkinson's disease (PD) research concerns its expression in hypothalamic nerve cells that co-express hypocretin/orexin [3] and which are prodigiously affected by the neurodegeneration in PD. These nerve cells have been implicated in the sleep disturbances that are often found in PD patients [9, 30].
###end p 7
###begin p 8
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 47 52 <span type="species:ncbi:9606">human</span>
Using a whole genome expression dataset of the human Parkinsonian nigra [19], we have identified NPTX2 as the most highly upregulated gene in a cohort of sporadic PD cases. Here we demonstrate that NPTX2 labels Lewy bodies in paraffin sections and that there is dysregulation of NPTX2 also in PD frontal cortex.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 20 25 <span type="species:ncbi:9606">human</span>
Tissue samples from human SN and frontal cortex
###end title 10
###begin p 11
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 565 570 <span type="species:ncbi:9606">human</span>
Some of the sporadic PD cases used in this study and several controls have been described previously [6, 19, 20]. Information on the cases employed for this project is provided in Supplemental Table. Brain tissue was obtained from the UK Parkinson's Disease Society Brain Bank at Imperial College London. The diagnostic work was performed in the Department of Neuropathology following international neuropathological consensus criteria for PD () which require use of alpha-synuclein as a molecular diagnostic marker. Ethics committee approval was available for all human tissue work of this study. For the dissection of the substantia nigra tissue (medial and lateral nigra were prepared separately), the portion of the midbrain containing the substantia nigra was separated from the brainstem distal to the mamillary bodies (45degrees angle cut) at the level of the third cranial nerve and the superior colliculi. A slice approximately 5 mm in depth was prepared containing both SN and the cross-sectioned red nucleus at the level of its greatest diameter. Then, the SN was dissected from the surrounding nuclei and the pars reticulata. Once the SN was isolated, it was divided into two portions, the medial SN and the lateral SN. In all cases where frontal lobe was used, the superior frontal gyrus was sampled at the same level.
###end p 11
###begin title 12
Quantitative real-time polymerase chain reaction
###end title 12
###begin p 13
###xml 87 90 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 226 228 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 611 613 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
Total RNA was extracted from PD and control cases and transcribed using the RETROscript(R) kit (Applied Biosystems, Warrington, UK) following the manufacturer's protocol. Primers for the internal control genes were as before [19]. Predesigned Taqman primers for NPTX2 (Hs00383983_m1) were purchased (Applied Biosystems) and Taqman mastermix (Applied Biosystems) was used. Each reaction was run in triplicate using an ABI PRISMtrade mark 7700 Sequence Detector (Applied Biosystems). For every gene tested, a negative control was run without cDNA template. Data analysis for real-time PCR (DART-PCR Version 1.0; [25]) was used to determine relative differences in NPTX2 mRNA expression between PD cases and controls (also see Supplemental Figure 1).
###end p 13
###begin title 14
In situ hybridization (ISH)
###end title 14
###begin p 15
###xml 84 86 84 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 456 458 456 458 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
ISH was performed using radioactive oligonucleotide probes as described previously [18, 29] Oligonucleotides were designed using NetPrimer software (Premier, BioSoft International, ). Two oligonucleotides complementary to NPTX2 mRNA at nts 899-932 (AGCCACAGGCAGATGGTGAAGGCGTACAGCTCAG-probe A) and nts 1364-1397 (TCGACGTTATTGTCCACCCACGG-GATGATGTTGC-probe B) were synthesized (Sigma Genosys, Poole, UK). Oligonucleotides were radioactively end-labelled with 35S-dATP (Perkin-Elmer, UK) using terminal deoxynucleotidyl transferase (Promega, UK).
###end p 15
###begin p 16
Snap frozen, unfixed post-mortem tissue blocks of the frontal cortex and SN were cut on a cryostat (12 mum), collected onto Superfrost Plus slides (VWR) and stored at -80degreesC. Before use, tissue sections were fixed for 5 min in fresh 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Pre-hybridisation treatment included acetylation in 0.25 M acetic anhydride/0.1 M triethanolamine, dehydration in graded alcohol (70-100% ethanols) and delipidation in 100% chloroform. Hybridisation with the oligonucleotide probe was performed overnight at 37degreesC. Post-hybridisation sections were washed in standard saline citrate solutions with increasing stringencies. The sections were dehydrated rapidly through graded alcohols (70-100% ethanol), air-dried, dipped in autoradiographic emulsion (LM1, GE Healthcare, Amersham, UK) and exposed for 5-6 weeks. The autoradiographic emulsion was developed, sections were counterstained with toluidine blue (VWR) for Nissl substance and mounted for visualisation using bright field microscopy for the counterstain and epi-polarized illumination for the silver grains of the autoradiographic emulsion. Control slides run to check for specificity of hybridization included competition with an excess of oligonucleotide (250 times) and the use of two probes to different portions of the mRNA of interest which produced identical patterns of signal. Black and white photographs of emulsion-coated sections were taken using a microscope provided with a Hamamatsu C4742-95 digital camera (Herrsching, Germany) and HiPic software (Herrsching) to capture images. Digital colour images were captured with a Retiga 1300 monochrome 12-bit camera using a color option provided by a RGB-HM-S filter (QImaging, Burnaby, BC, Canada) and QCapture 1.1.6 software (QImaging). Adobe Photoshop was used to assemble images.
###end p 16
###begin title 17
Immunohistochemistry
###end title 17
###begin p 18
###xml 223 225 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 272 276 <span type="species:ncbi:9925">goat</span>
###xml 370 375 <span type="species:ncbi:10090">mouse</span>
###xml 588 593 <span type="species:ncbi:9796">horse</span>
###xml 599 604 <span type="species:ncbi:10090">mouse</span>
Paraffin embedded tissue sections (8 mum) were used for all stainings. No antigen retrieval was required for NPTX2 whereas for alpha-synuclein (SNCA) antibody staining sections were treated with 80% formic acid for 60 min [24]. Adjacent sections from SN were stained with goat polyclonal anti-NPTX2 antibody (NP2 N-20, sc-12125; Santa Cruz Biotechnology Inc.; 1:25) and mouse monoclonal anti-SNCA (BD Transduction Laboratories, catalogue number 610787; 1:1,000) overnight (4degreesC). Secondary antibodies used were gG-HRP (sc-2020; Santa Cruz Biotechnology Inc.; 1:100) and biotinylated horse anti-mouse (B-2000; Vector Laboratories, 1:100), respectively. The ABC kit (Elite 6100, Vector Laboratories) was used for visualisation using 3,3'-diaminobenzidine tetrahydrochloride (0.02%; Sigma, UK). Sections were counter-stained in Mayer's haemalum.
###end p 18
###begin p 19
###xml 293 297 <span type="species:ncbi:9925">goat</span>
###xml 303 309 <span type="species:ncbi:9986">rabbit</span>
###xml 401 406 <span type="species:ncbi:10090">mouse</span>
For fluorescence microscopy, anti-SNCA (1:1,000) and anti-NPTX2 (1:25) were added to the sections sequentially (each was incubated overnight at 4degreesC). For the detection of the primary antibodies, sections were rinsed in 0.1 M Tris buffered saline (TBS) and then incubated with either the goat anti-rabbit IgG tagged with Alexa Fluor 546 (red) for 1 h at room temperature or the biotinylated anti-mouse antibody (Vector Laboratories 1:100) for 1 hour followed by incubation with streptavidin Alex Fluor 488 (green) for 1 h at room temperature. Finally, tissue sections were rinsed in TBS and incubated in sudan black for 10 min before mounting in 80% Tris-buffered glycerol.
###end p 19
###begin title 20
Western blotting
###end title 20
###begin p 21
###xml 952 956 <span type="species:ncbi:9925">goat</span>
###xml 1215 1226 <span type="species:ncbi:3704">horseradish</span>
Snap frozen midbrain tissue samples containing SN from PD and control cases were homogenized with RIPA buffer (pH 8), heated to 70degreesC for 10 min and subsequently centrifuged (13,000 rpm, 10 min). The protein supernatant was removed and the concentration of protein determined (BIO-RAD protein reagent; BIO-RAD, UK) using a spectrophotometer. Denaturing gels were run using 30 mug of protein from each sample in 19.5 mul RIPA buffer, 3 mul beta-mercaptoethanol and 7.5 mul lithium dodecyl sulphate sample buffer (Invitrogen, UK). NuPAGE Bis-Tris 4-12% polyacrylamide gels (Invitrogen) were run in NuPage SDS running buffer (Invitrogen). Gels were blotted onto nitrocellulose membranes (Invitrogen), immersed in NuPage LDS transfer buffer (Invitrogen) in a cold room (4degreesC) overnight applying 30 V. Successful protein transfer was verified by staining the membrane in Ponceau S (VWR, UK) for 10 min. Prior to overnight incubation in polyclonal goat antibody to NPTX2 (N-20), membranes were washed in phosphate buffered saline (PBS) containing 0.1% Tween 20 and subsequently rinsed in PBS/0.1% Tween 20 containing 5% skimmed milk (blocking step) for 30 min. Incubation with the secondary antibody coupled to horseradish peroxidase (1:5,000; Vector Labs, UK) was carried out for 1 h at room temperature. Visualization of antibody binding using enhanced chemilluminescence (ECL; Amersham Biosciences, UK) was performed according to the manufacturer's instructions.
###end p 21
###begin title 22
Semi-quantitative ratings
###end title 22
###begin p 23
The NPTX2 labelled SN sections were examined by two independent observers blinded to the identity of the respective cases. The occurrence of NPTX2 immunoreactive profiles in the SN was scored for the overall burden of NPTX2 immunoreactive deposits using a seven-point scale ranging from 0-0.5 to 3 (absent to severe). Correlation analysis (Spearman; Sigmatstat 2.03) was conducted within the PD cohort for NPTX2 mRNA expression (log 2 microarray data) and the corresponding semi-quantitative immunocytochemical results.
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
NPTX2 is a novel component of Lewy bodies
###end title 25
###begin p 26
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 292 293 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 336 341 336 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">log&#160;2</sub>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 577 578 577 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 702 708 702 708 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 818 820 818 820 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a </bold>
###xml 919 921 919 921 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b </bold>
###xml 987 988 987 988 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1177 1179 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1231 1235 1231 1235 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d, e</bold>
###xml 1421 1426 1421 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 1430 1431 1430 1431 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1442 1448 1442 1448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 1452 1453 1452 1453 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1544 1553 1544 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 1635 1636 1635 1636 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1804 1813 1804 1813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 1820 1825 1820 1825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 1890 1891 1890 1891 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1896 1897 1896 1897 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1931 1932 1931 1932 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1954 1955 1953 1954 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1957 1958 1956 1957 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1969 1970 1967 1968 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1986 1987 1983 1984 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 708 1988 708 1985 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="27">Neuronal pentraxin II (NPTX2) is strongly upregulated in substantia nigra and cerebral cortex of PD patients. <bold>a </bold>NPTX2 immunocytochemistry demonstrating specific staining of Lewy bodies in a dopaminergic neuron. <bold>b </bold>Western blotting confirms specificity of the anti-NPTX2 antibody. <bold>c</bold> qRT-PCR shows highly increased levels of NPTX2 mRNA in substantia nigra and, to a lesser extent, in frontal cortex. The arbitrary units along the ordinate represent relative fold changes [<xref ref-type="bibr" rid="CR25">25</xref>]. The control value is 1; error bars indicate SEM. <bold>d, e</bold> In situ hybridisation demonstrates NPTX2 mRNA expression in nerve cells as well as glia in both substantia nigra and frontal cortex. Labelling is also found over non-pigmented neurons (<italic>arrow</italic> in <bold>d</bold>, SN). The <italic>arrows</italic> in <bold>e</bold> mark glial cells (cortex). In addition, there is autoradiographic signal in the neuropil (<italic>asterisks</italic>) which would be in keeping with the presumed dendritic expression of NPTX2 mRNA. <bold>f</bold> NPTX2 immunocytochemistry of cortical neuropil reveals occasional intercellular patches of &#8220;arborised&#8221; labelling also possibly suggestive of a dendritic localisation (<italic>asterisks</italic>). The <italic>arrow</italic> points to a NPTX2 immunoreactive glial cell. Counterstaining in <bold>a</bold> and <bold>f</bold>, haemalum, and toluidine blue in <bold>d</bold>. Scale bars: 20&#160;&#956;m (<bold>a</bold>, <bold>f</bold>), 50&#160;&#956;m (<bold>d</bold>), and 100&#160;&#956;m (<bold>e</bold>)</p>
###xml 708 1988 708 1985 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="27">Neuronal pentraxin II (NPTX2) is strongly upregulated in substantia nigra and cerebral cortex of PD patients. <bold>a </bold>NPTX2 immunocytochemistry demonstrating specific staining of Lewy bodies in a dopaminergic neuron. <bold>b </bold>Western blotting confirms specificity of the anti-NPTX2 antibody. <bold>c</bold> qRT-PCR shows highly increased levels of NPTX2 mRNA in substantia nigra and, to a lesser extent, in frontal cortex. The arbitrary units along the ordinate represent relative fold changes [<xref ref-type="bibr" rid="CR25">25</xref>]. The control value is 1; error bars indicate SEM. <bold>d, e</bold> In situ hybridisation demonstrates NPTX2 mRNA expression in nerve cells as well as glia in both substantia nigra and frontal cortex. Labelling is also found over non-pigmented neurons (<italic>arrow</italic> in <bold>d</bold>, SN). The <italic>arrows</italic> in <bold>e</bold> mark glial cells (cortex). In addition, there is autoradiographic signal in the neuropil (<italic>asterisks</italic>) which would be in keeping with the presumed dendritic expression of NPTX2 mRNA. <bold>f</bold> NPTX2 immunocytochemistry of cortical neuropil reveals occasional intercellular patches of &#8220;arborised&#8221; labelling also possibly suggestive of a dendritic localisation (<italic>asterisks</italic>). The <italic>arrow</italic> points to a NPTX2 immunoreactive glial cell. Counterstaining in <bold>a</bold> and <bold>f</bold>, haemalum, and toluidine blue in <bold>d</bold>. Scale bars: 20&#160;&#956;m (<bold>a</bold>, <bold>f</bold>), 50&#160;&#956;m (<bold>d</bold>), and 100&#160;&#956;m (<bold>e</bold>)</p></caption>
###xml 1988 1988 1985 1985 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2007_309_Fig1_HTML" id="MO2"/>
###xml 702 1988 702 1985 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="27">Neuronal pentraxin II (NPTX2) is strongly upregulated in substantia nigra and cerebral cortex of PD patients. <bold>a </bold>NPTX2 immunocytochemistry demonstrating specific staining of Lewy bodies in a dopaminergic neuron. <bold>b </bold>Western blotting confirms specificity of the anti-NPTX2 antibody. <bold>c</bold> qRT-PCR shows highly increased levels of NPTX2 mRNA in substantia nigra and, to a lesser extent, in frontal cortex. The arbitrary units along the ordinate represent relative fold changes [<xref ref-type="bibr" rid="CR25">25</xref>]. The control value is 1; error bars indicate SEM. <bold>d, e</bold> In situ hybridisation demonstrates NPTX2 mRNA expression in nerve cells as well as glia in both substantia nigra and frontal cortex. Labelling is also found over non-pigmented neurons (<italic>arrow</italic> in <bold>d</bold>, SN). The <italic>arrows</italic> in <bold>e</bold> mark glial cells (cortex). In addition, there is autoradiographic signal in the neuropil (<italic>asterisks</italic>) which would be in keeping with the presumed dendritic expression of NPTX2 mRNA. <bold>f</bold> NPTX2 immunocytochemistry of cortical neuropil reveals occasional intercellular patches of &#8220;arborised&#8221; labelling also possibly suggestive of a dendritic localisation (<italic>asterisks</italic>). The <italic>arrow</italic> points to a NPTX2 immunoreactive glial cell. Counterstaining in <bold>a</bold> and <bold>f</bold>, haemalum, and toluidine blue in <bold>d</bold>. Scale bars: 20&#160;&#956;m (<bold>a</bold>, <bold>f</bold>), 50&#160;&#956;m (<bold>d</bold>), and 100&#160;&#956;m (<bold>e</bold>)</p></caption><graphic position="anchor" xlink:href="401_2007_309_Fig1_HTML" id="MO2"/></fig>
###xml 808 816 <span type="species:ncbi:9606">patients</span>
We demonstrate here that NPTX2 protein in the Parkinsonian substantia nigra localizes to Lewy bodies, Lewy neurites and some glial cells. NPTX2 is the most upregulated gene in our microarray data set [19]. It shows the greatest difference between disease and control nigrae (probe 213479_at, P = 4.60051E-07, differential expression, DElog 2, 3.0036217 which is equivalent to >800%). Many neurons show more than one NPTX2 immunoreactive LB (Fig. 1a). Western blotting confirmed specificity of the antibody revealing a band, which corresponds to the NPTX2 monomer (47 kDa; Fig. 1b). Very strong upregulation of NPTX2 mRNA expression in PD was confirmed by means of quantitative real time-PCR (Fig. 1c). Fig. 1Neuronal pentraxin II (NPTX2) is strongly upregulated in substantia nigra and cerebral cortex of PD patients. a NPTX2 immunocytochemistry demonstrating specific staining of Lewy bodies in a dopaminergic neuron. b Western blotting confirms specificity of the anti-NPTX2 antibody. c qRT-PCR shows highly increased levels of NPTX2 mRNA in substantia nigra and, to a lesser extent, in frontal cortex. The arbitrary units along the ordinate represent relative fold changes [25]. The control value is 1; error bars indicate SEM. d, e In situ hybridisation demonstrates NPTX2 mRNA expression in nerve cells as well as glia in both substantia nigra and frontal cortex. Labelling is also found over non-pigmented neurons (arrow in d, SN). The arrows in e mark glial cells (cortex). In addition, there is autoradiographic signal in the neuropil (asterisks) which would be in keeping with the presumed dendritic expression of NPTX2 mRNA. f NPTX2 immunocytochemistry of cortical neuropil reveals occasional intercellular patches of "arborised" labelling also possibly suggestive of a dendritic localisation (asterisks). The arrow points to a NPTX2 immunoreactive glial cell. Counterstaining in a and f, haemalum, and toluidine blue in d. Scale bars: 20 mum (a, f), 50 mum (d), and 100 mum (e)
###end p 26
###begin p 27
###xml 110 112 110 112 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a </bold>
###xml 211 213 211 213 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b </bold>
###xml 279 280 279 280 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 523 527 523 527 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d, e</bold>
###xml 713 718 713 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 722 723 722 723 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 734 740 734 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 744 745 744 745 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 836 845 836 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 927 928 927 928 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1096 1105 1096 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 1112 1117 1112 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 1182 1183 1182 1183 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1188 1189 1188 1189 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1223 1224 1223 1224 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1246 1247 1245 1246 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1249 1250 1248 1249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1261 1262 1259 1260 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1278 1279 1275 1276 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Neuronal pentraxin II (NPTX2) is strongly upregulated in substantia nigra and cerebral cortex of PD patients. a NPTX2 immunocytochemistry demonstrating specific staining of Lewy bodies in a dopaminergic neuron. b Western blotting confirms specificity of the anti-NPTX2 antibody. c qRT-PCR shows highly increased levels of NPTX2 mRNA in substantia nigra and, to a lesser extent, in frontal cortex. The arbitrary units along the ordinate represent relative fold changes [25]. The control value is 1; error bars indicate SEM. d, e In situ hybridisation demonstrates NPTX2 mRNA expression in nerve cells as well as glia in both substantia nigra and frontal cortex. Labelling is also found over non-pigmented neurons (arrow in d, SN). The arrows in e mark glial cells (cortex). In addition, there is autoradiographic signal in the neuropil (asterisks) which would be in keeping with the presumed dendritic expression of NPTX2 mRNA. f NPTX2 immunocytochemistry of cortical neuropil reveals occasional intercellular patches of "arborised" labelling also possibly suggestive of a dendritic localisation (asterisks). The arrow points to a NPTX2 immunoreactive glial cell. Counterstaining in a and f, haemalum, and toluidine blue in d. Scale bars: 20 mum (a, f), 50 mum (d), and 100 mum (e)
###end p 27
###begin title 28
Localisation of NPTX2 and SNCA protein
###end title 28
###begin p 29
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1298 1299 1298 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1418 1419 1418 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1472 1473 1472 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1770 1771 1770 1771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 2008 2009 2008 2009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 2176 2177 2176 2177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2187 2188 2187 2188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2204 2205 2204 2205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 2296 2296 2296 2296 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2007_309_Figa_HTML" id="MO1"/>
###xml 2296 2302 2296 2302 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 2348 2352 2348 2352 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a, b</bold>
###xml 2503 2514 2503 2514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">large arrow</italic>
###xml 2518 2519 2518 2519 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2684 2690 2684 2690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 2694 2695 2694 2695 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2942 2952 2942 2952 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow head</italic>
###xml 2956 2957 2956 2957 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2974 2983 2974 2983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 2987 2988 2987 2988 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3003 3011 3003 3011 <bold xmlns:xlink="http://www.w3.org/1999/xlink"> c, d, e</bold>
###xml 3090 3093 3090 3093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 3095 3096 3095 3096 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 3119 3124 3119 3124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 3126 3127 3126 3127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 3158 3164 3158 3164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 3168 3169 3168 3169 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 3183 3189 3183 3189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 3206 3207 3206 3207 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 3229 3230 3228 3229 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3232 3233 3231 3232 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 3248 3249 3246 3247 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 3250 3251 3248 3249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 2302 3266 2302 3264 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Co-localisation of NPTX2 and alpha-synuclein. <bold>a, b</bold> NPTX2 and alpha-synuclein immunolabelling of adjacent tissue sections demonstrates significant but not complete overlap between the two proteins. The <italic>large arrow</italic> in <bold>a</bold> denotes the same Lewy body-containing dopaminergic nigral neuron. Small granular cytoplasmic deposits showing alpha-synuclein immunoreactivity in some nerve cells (<italic>arrows</italic> in <bold>b</bold>) are NPTX2 negative. These aggresomes are sometimes difficult to distinguish from neuromelanin granules based on staining alone but their cytoplasmic distribution is also different from the latter. In contrast, Lewy neurites are double-labelled (<italic>arrow head</italic> in <bold>b</bold>). Neuromelanin (<italic>asterisks</italic> in <bold>a</bold>) is unstained.<bold> c, d, e</bold> Dual immunofluorecence demonstrates co-localisation of neuronal pentraxin II (<italic>red</italic>, <bold>c</bold>) and alpha-synuclein (<italic>green</italic>, <bold>d</bold>). Double-labelled structures (<italic>arrows</italic> in <bold>c</bold>) light up in <italic>yellow</italic> in the overlay (<bold>e</bold>). Scale bar: 40&#160;&#956;m (<bold>a</bold>, <bold>b</bold>), and 80&#160;&#956;m (<bold>c</bold>&#8211;<bold>e</bold>), respectively</p>
###xml 2302 3266 2302 3264 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Co-localisation of NPTX2 and alpha-synuclein. <bold>a, b</bold> NPTX2 and alpha-synuclein immunolabelling of adjacent tissue sections demonstrates significant but not complete overlap between the two proteins. The <italic>large arrow</italic> in <bold>a</bold> denotes the same Lewy body-containing dopaminergic nigral neuron. Small granular cytoplasmic deposits showing alpha-synuclein immunoreactivity in some nerve cells (<italic>arrows</italic> in <bold>b</bold>) are NPTX2 negative. These aggresomes are sometimes difficult to distinguish from neuromelanin granules based on staining alone but their cytoplasmic distribution is also different from the latter. In contrast, Lewy neurites are double-labelled (<italic>arrow head</italic> in <bold>b</bold>). Neuromelanin (<italic>asterisks</italic> in <bold>a</bold>) is unstained.<bold> c, d, e</bold> Dual immunofluorecence demonstrates co-localisation of neuronal pentraxin II (<italic>red</italic>, <bold>c</bold>) and alpha-synuclein (<italic>green</italic>, <bold>d</bold>). Double-labelled structures (<italic>arrows</italic> in <bold>c</bold>) light up in <italic>yellow</italic> in the overlay (<bold>e</bold>). Scale bar: 40&#160;&#956;m (<bold>a</bold>, <bold>b</bold>), and 80&#160;&#956;m (<bold>c</bold>&#8211;<bold>e</bold>), respectively</p></caption>
###xml 3266 3266 3264 3264 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2007_309_Fig2_HTML" id="MO3"/>
###xml 2296 3266 2296 3264 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="30">Co-localisation of NPTX2 and alpha-synuclein. <bold>a, b</bold> NPTX2 and alpha-synuclein immunolabelling of adjacent tissue sections demonstrates significant but not complete overlap between the two proteins. The <italic>large arrow</italic> in <bold>a</bold> denotes the same Lewy body-containing dopaminergic nigral neuron. Small granular cytoplasmic deposits showing alpha-synuclein immunoreactivity in some nerve cells (<italic>arrows</italic> in <bold>b</bold>) are NPTX2 negative. These aggresomes are sometimes difficult to distinguish from neuromelanin granules based on staining alone but their cytoplasmic distribution is also different from the latter. In contrast, Lewy neurites are double-labelled (<italic>arrow head</italic> in <bold>b</bold>). Neuromelanin (<italic>asterisks</italic> in <bold>a</bold>) is unstained.<bold> c, d, e</bold> Dual immunofluorecence demonstrates co-localisation of neuronal pentraxin II (<italic>red</italic>, <bold>c</bold>) and alpha-synuclein (<italic>green</italic>, <bold>d</bold>). Double-labelled structures (<italic>arrows</italic> in <bold>c</bold>) light up in <italic>yellow</italic> in the overlay (<bold>e</bold>). Scale bar: 40&#160;&#956;m (<bold>a</bold>, <bold>b</bold>), and 80&#160;&#956;m (<bold>c</bold>&#8211;<bold>e</bold>), respectively</p></caption><graphic position="anchor" xlink:href="401_2007_309_Fig2_HTML" id="MO3"/></fig>
###xml 3266 3272 3264 3270 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 3370 3371 3368 3369 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3446 3447 3444 3445 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 3450 3456 3448 3454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 3602 3615 3600 3613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">longer arrows</italic>
###xml 3618 3620 3616 3618 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b </bold>
###xml 3620 3626 3618 3624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 3675 3676 3673 3674 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 3860 3871 3858 3869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">long arrows</italic>
###xml 4177 4189 4175 4187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">small arrows</italic>
###xml 4297 4298 4295 4296 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 4305 4306 4303 4304 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 4316 4317 4314 4315 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 3272 4336 3270 4333 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31">Morphology of neuronal pentraxin II immunoreactive deposits in the Parkinsonian substantia nigra. <bold>a</bold> Lewy bodies are labelled which often show a crennelated surface (also see <bold>c</bold>). <italic>Arrows</italic> of the inset point to NPTX2 labelled connections/&#8220;bridges&#8221; between small Lewy bodies. Cross-sectioned axon bundles in white matter are numerous (<italic>longer arrows</italic>). <bold>b </bold><italic>Arrows</italic> point to Lewy neurites in the substantia nigra. <bold>c</bold> NPTX2 is present in pre-Lewy bodies and glial cells. Labelling can be seen inside the cytoplasm of nerve cells in the neighbourhood and often directly attached to mature Lewy bodies (<italic>long arrows</italic>). Note the crenellated surface of compacted NPTX2 deposits (centre and Lewy body at the bottom of the figure) due to hair-like projections, which radiate into the cytoplasm. NPTX2 immunoreactivity is also present in glial cells. A subset of astrocytes as well as possibly microglia appear to be labelled (<italic>small arrows</italic>). The short arrow in the lower left points to what appears to be nuclear immunoreactivity. Scale bars: 40 (<bold>a</bold>), 50 (<bold>b</bold>) and 30 (<bold>c</bold>) &#956;m, respectively</p>
###xml 3272 4336 3270 4333 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="31">Morphology of neuronal pentraxin II immunoreactive deposits in the Parkinsonian substantia nigra. <bold>a</bold> Lewy bodies are labelled which often show a crennelated surface (also see <bold>c</bold>). <italic>Arrows</italic> of the inset point to NPTX2 labelled connections/&#8220;bridges&#8221; between small Lewy bodies. Cross-sectioned axon bundles in white matter are numerous (<italic>longer arrows</italic>). <bold>b </bold><italic>Arrows</italic> point to Lewy neurites in the substantia nigra. <bold>c</bold> NPTX2 is present in pre-Lewy bodies and glial cells. Labelling can be seen inside the cytoplasm of nerve cells in the neighbourhood and often directly attached to mature Lewy bodies (<italic>long arrows</italic>). Note the crenellated surface of compacted NPTX2 deposits (centre and Lewy body at the bottom of the figure) due to hair-like projections, which radiate into the cytoplasm. NPTX2 immunoreactivity is also present in glial cells. A subset of astrocytes as well as possibly microglia appear to be labelled (<italic>small arrows</italic>). The short arrow in the lower left points to what appears to be nuclear immunoreactivity. Scale bars: 40 (<bold>a</bold>), 50 (<bold>b</bold>) and 30 (<bold>c</bold>) &#956;m, respectively</p></caption>
###xml 4336 4336 4333 4333 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2007_309_Fig3_HTML" id="MO4"/>
###xml 3266 4336 3264 4333 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="31">Morphology of neuronal pentraxin II immunoreactive deposits in the Parkinsonian substantia nigra. <bold>a</bold> Lewy bodies are labelled which often show a crennelated surface (also see <bold>c</bold>). <italic>Arrows</italic> of the inset point to NPTX2 labelled connections/&#8220;bridges&#8221; between small Lewy bodies. Cross-sectioned axon bundles in white matter are numerous (<italic>longer arrows</italic>). <bold>b </bold><italic>Arrows</italic> point to Lewy neurites in the substantia nigra. <bold>c</bold> NPTX2 is present in pre-Lewy bodies and glial cells. Labelling can be seen inside the cytoplasm of nerve cells in the neighbourhood and often directly attached to mature Lewy bodies (<italic>long arrows</italic>). Note the crenellated surface of compacted NPTX2 deposits (centre and Lewy body at the bottom of the figure) due to hair-like projections, which radiate into the cytoplasm. NPTX2 immunoreactivity is also present in glial cells. A subset of astrocytes as well as possibly microglia appear to be labelled (<italic>small arrows</italic>). The short arrow in the lower left points to what appears to be nuclear immunoreactivity. Scale bars: 40 (<bold>a</bold>), 50 (<bold>b</bold>) and 30 (<bold>c</bold>) &#956;m, respectively</p></caption><graphic position="anchor" xlink:href="401_2007_309_Fig3_HTML" id="MO4"/></fig>
###xml 4336 4343 4333 4340 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 4343 4493 4340 4490 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">Correlation analysis for NPTX2 microarray expression data and the corresponding semi-quantitative immunocytochemical ratings for eight of the PD cases</p>
###xml 4343 4493 4340 4490 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">Correlation analysis for NPTX2 microarray expression data and the corresponding semi-quantitative immunocytochemical ratings for eight of the PD cases</p></caption>
###xml 4493 4504 4490 4501 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case number</th>
###xml 4504 4533 4501 4530 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Expression NPTX2 mRNA (log&#160;2)</th>
###xml 4533 4573 4530 4570 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Semi-quantitative ratings NPTX2 IR in SN</th>
###xml 4493 4573 4490 4570 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Case number</th><th align="left">Expression NPTX2 mRNA (log&#160;2)</th><th align="left">Semi-quantitative ratings NPTX2 IR in SN</th></tr>
###xml 4493 4573 4490 4570 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Case number</th><th align="left">Expression NPTX2 mRNA (log&#160;2)</th><th align="left">Semi-quantitative ratings NPTX2 IR in SN</th></tr></thead>
###xml 4573 4574 4570 4571 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 4574 4585 4571 4582 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.278105587</td>
###xml 4585 4586 4582 4583 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 4573 4586 4570 4583 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2</td><td char="." align="char">7.278105587</td><td char="." align="char">1</td></tr>
###xml 4586 4587 4583 4584 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 4587 4598 4584 4595 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">9.800657274</td>
###xml 4598 4599 4595 4596 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 4586 4599 4583 4596 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3</td><td char="." align="char">9.800657274</td><td char="." align="char">3</td></tr>
###xml 4599 4600 4596 4597 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 4600 4611 4597 4608 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.739679364</td>
###xml 4611 4614 4608 4611 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.5</td>
###xml 4599 4614 4596 4611 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6</td><td char="." align="char">8.739679364</td><td char="." align="char">1.5</td></tr>
###xml 4614 4615 4611 4612 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7</td>
###xml 4615 4625 4612 4622 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.44508108</td>
###xml 4625 4628 4622 4625 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.5</td>
###xml 4614 4628 4611 4625 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">7</td><td char="." align="char">8.44508108</td><td char="." align="char">1.5</td></tr>
###xml 4628 4629 4625 4626 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9</td>
###xml 4629 4640 4626 4637 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3.418203444</td>
###xml 4640 4643 4637 4640 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.5</td>
###xml 4628 4643 4625 4640 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">9</td><td char="." align="char">3.418203444</td><td char="." align="char">0.5</td></tr>
###xml 4643 4645 4640 4642 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12</td>
###xml 4645 4656 4642 4653 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.980139578</td>
###xml 4656 4657 4653 4654 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 4643 4657 4640 4654 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">12</td><td char="." align="char">7.980139578</td><td char="." align="char">1</td></tr>
###xml 4657 4659 4654 4656 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">14</td>
###xml 4659 4670 4656 4667 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8.965264821</td>
###xml 4670 4671 4667 4668 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 4657 4671 4654 4668 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">14</td><td char="." align="char">8.965264821</td><td char="." align="char">2</td></tr>
###xml 4671 4673 4668 4670 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15</td>
###xml 4673 4684 4670 4681 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6.414495823</td>
###xml 4684 4685 4681 4682 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 4671 4685 4668 4682 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">15</td><td char="." align="char">6.414495823</td><td char="." align="char">1</td></tr>
###xml 4573 4685 4570 4682 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">2</td><td char="." align="char">7.278105587</td><td char="." align="char">1</td></tr><tr><td align="left">3</td><td char="." align="char">9.800657274</td><td char="." align="char">3</td></tr><tr><td align="left">6</td><td char="." align="char">8.739679364</td><td char="." align="char">1.5</td></tr><tr><td align="left">7</td><td char="." align="char">8.44508108</td><td char="." align="char">1.5</td></tr><tr><td align="left">9</td><td char="." align="char">3.418203444</td><td char="." align="char">0.5</td></tr><tr><td align="left">12</td><td char="." align="char">7.980139578</td><td char="." align="char">1</td></tr><tr><td align="left">14</td><td char="." align="char">8.965264821</td><td char="." align="char">2</td></tr><tr><td align="left">15</td><td char="." align="char">6.414495823</td><td char="." align="char">1</td></tr></tbody>
###xml 4493 4685 4490 4682 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Case number</th><th align="left">Expression NPTX2 mRNA (log&#160;2)</th><th align="left">Semi-quantitative ratings NPTX2 IR in SN</th></tr></thead><tbody><tr><td align="left">2</td><td char="." align="char">7.278105587</td><td char="." align="char">1</td></tr><tr><td align="left">3</td><td char="." align="char">9.800657274</td><td char="." align="char">3</td></tr><tr><td align="left">6</td><td char="." align="char">8.739679364</td><td char="." align="char">1.5</td></tr><tr><td align="left">7</td><td char="." align="char">8.44508108</td><td char="." align="char">1.5</td></tr><tr><td align="left">9</td><td char="." align="char">3.418203444</td><td char="." align="char">0.5</td></tr><tr><td align="left">12</td><td char="." align="char">7.980139578</td><td char="." align="char">1</td></tr><tr><td align="left">14</td><td char="." align="char">8.965264821</td><td char="." align="char">2</td></tr><tr><td align="left">15</td><td char="." align="char">6.414495823</td><td char="." align="char">1</td></tr></tbody></table>
###xml 4336 4685 4333 4682 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="32">Correlation analysis for NPTX2 microarray expression data and the corresponding semi-quantitative immunocytochemical ratings for eight of the PD cases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case number</th><th align="left">Expression NPTX2 mRNA (log&#160;2)</th><th align="left">Semi-quantitative ratings NPTX2 IR in SN</th></tr></thead><tbody><tr><td align="left">2</td><td char="." align="char">7.278105587</td><td char="." align="char">1</td></tr><tr><td align="left">3</td><td char="." align="char">9.800657274</td><td char="." align="char">3</td></tr><tr><td align="left">6</td><td char="." align="char">8.739679364</td><td char="." align="char">1.5</td></tr><tr><td align="left">7</td><td char="." align="char">8.44508108</td><td char="." align="char">1.5</td></tr><tr><td align="left">9</td><td char="." align="char">3.418203444</td><td char="." align="char">0.5</td></tr><tr><td align="left">12</td><td char="." align="char">7.980139578</td><td char="." align="char">1</td></tr><tr><td align="left">14</td><td char="." align="char">8.965264821</td><td char="." align="char">2</td></tr><tr><td align="left">15</td><td char="." align="char">6.414495823</td><td char="." align="char">1</td></tr></tbody></table></table-wrap>
In situ hybridisation revealed expression of NPTX2 mRNA in nerve cells as well as glia in both SN and frontal cortex, respectively (Fig. 1d, e). NPTX2 immunoreactive LBs were also observed in the frontal cortex and there were ramified ("arborised") NPTX2 positive profiles of cell processes in the neuropil (Fig. 1f). Analysis of adjacent tissue sections demonstrated co-localisation of NPTX2 and SNCA in the same nerve cells (Fig. 2a, b). This was confirmed by dual immunofluorescence (Fig. 2c-e). Overall, NPTX2 immunoreactive neuronal deposits mapped very closely to alpha-synuclein aggregates, both cellularly and subcellulary, and NPTX2 was also observed in incidental Lewy bodies (for a summary of cases used see Supplemental Table of Electronic Supplementary Material). In contrast, no NPTX2 immunoreactive intracellular aggregates were observed in two cases of tauopathy, i.e. progressive supranuclear palsy, where alpha-synuclein deposits are also not found. However, not all SNCA immunoreactive profiles were NPTX2 positive, i.e. the number of SNCA labelled nerve cells outnumbered that of NPTX2 stained ones (about 2-3:1). In addition, in some nerve cells, SNCA immunopositivity was observed as small granular cytoplasmic deposits ("aggresomes") that lacked NPTX2 immunoreactivity (Fig. 2a, b). However, NPTX2 immunoepitopes were found to decorate the halo of LBs more distinctly than alpha-synuclein (Fig. 3). Strongly NPTX2 immunoreactive Lewy neurites (Fig. 3) were also found. Cases with high levels of NPTX2 protein expression showed a larger alpha-synuclein burden. We estimate that about one-third of the alpha-synuclein immunoreactive protein deposits also stain for NPTX2. Labelling of normal appearing axons by NPTX2 was widespread in both PD (Fig. 3) and control brains. Glial cytoplasmic (Papp-Lantos) inclusions of multiple system atrophy (MSA) were NPTX2 positive (not shown) and in PD a sizeable number of glial cells expressed NPTX2 protein that appeared to be SNCA negative (Fig. 3). Correlation analysis for NPTX2 microarray expression data and the corresponding semi-quantitative immunocytochemical case ratings showed a significant correlation (r = 0.970, P < 0.001; Table 1). However, there was no association between NPTX2 expression and duration of the disease. Fig. 2Co-localisation of NPTX2 and alpha-synuclein. a, b NPTX2 and alpha-synuclein immunolabelling of adjacent tissue sections demonstrates significant but not complete overlap between the two proteins. The large arrow in a denotes the same Lewy body-containing dopaminergic nigral neuron. Small granular cytoplasmic deposits showing alpha-synuclein immunoreactivity in some nerve cells (arrows in b) are NPTX2 negative. These aggresomes are sometimes difficult to distinguish from neuromelanin granules based on staining alone but their cytoplasmic distribution is also different from the latter. In contrast, Lewy neurites are double-labelled (arrow head in b). Neuromelanin (asterisks in a) is unstained. c, d, e Dual immunofluorecence demonstrates co-localisation of neuronal pentraxin II (red, c) and alpha-synuclein (green, d). Double-labelled structures (arrows in c) light up in yellow in the overlay (e). Scale bar: 40 mum (a, b), and 80 mum (c-e), respectivelyFig. 3Morphology of neuronal pentraxin II immunoreactive deposits in the Parkinsonian substantia nigra. a Lewy bodies are labelled which often show a crennelated surface (also see c). Arrows of the inset point to NPTX2 labelled connections/"bridges" between small Lewy bodies. Cross-sectioned axon bundles in white matter are numerous (longer arrows). b Arrows point to Lewy neurites in the substantia nigra. c NPTX2 is present in pre-Lewy bodies and glial cells. Labelling can be seen inside the cytoplasm of nerve cells in the neighbourhood and often directly attached to mature Lewy bodies (long arrows). Note the crenellated surface of compacted NPTX2 deposits (centre and Lewy body at the bottom of the figure) due to hair-like projections, which radiate into the cytoplasm. NPTX2 immunoreactivity is also present in glial cells. A subset of astrocytes as well as possibly microglia appear to be labelled (small arrows). The short arrow in the lower left points to what appears to be nuclear immunoreactivity. Scale bars: 40 (a), 50 (b) and 30 (c) mum, respectivelyTable 1Correlation analysis for NPTX2 microarray expression data and the corresponding semi-quantitative immunocytochemical ratings for eight of the PD casesCase numberExpression NPTX2 mRNA (log 2)Semi-quantitative ratings NPTX2 IR in SN27.278105587139.800657274368.7396793641.578.445081081.593.4182034440.5127.9801395781148.9652648212156.4144958231
###end p 29
###begin p 30
###xml 46 50 46 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a, b</bold>
###xml 201 212 201 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">large arrow</italic>
###xml 216 217 216 217 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 392 393 392 393 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 640 650 640 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow head</italic>
###xml 654 655 654 655 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 672 681 672 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisks</italic>
###xml 685 686 685 686 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 701 709 701 709 <bold xmlns:xlink="http://www.w3.org/1999/xlink"> c, d, e</bold>
###xml 788 791 788 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 793 794 793 794 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 817 822 817 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 824 825 824 825 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 856 862 856 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrows</italic>
###xml 866 867 866 867 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 881 887 881 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">yellow</italic>
###xml 904 905 904 905 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 927 928 926 927 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 930 931 929 930 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 946 947 944 945 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 948 949 946 947 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
Co-localisation of NPTX2 and alpha-synuclein. a, b NPTX2 and alpha-synuclein immunolabelling of adjacent tissue sections demonstrates significant but not complete overlap between the two proteins. The large arrow in a denotes the same Lewy body-containing dopaminergic nigral neuron. Small granular cytoplasmic deposits showing alpha-synuclein immunoreactivity in some nerve cells (arrows in b) are NPTX2 negative. These aggresomes are sometimes difficult to distinguish from neuromelanin granules based on staining alone but their cytoplasmic distribution is also different from the latter. In contrast, Lewy neurites are double-labelled (arrow head in b). Neuromelanin (asterisks in a) is unstained. c, d, e Dual immunofluorecence demonstrates co-localisation of neuronal pentraxin II (red, c) and alpha-synuclein (green, d). Double-labelled structures (arrows in c) light up in yellow in the overlay (e). Scale bar: 40 mum (a, b), and 80 mum (c-e), respectively
###end p 30
###begin p 31
###xml 98 99 98 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 174 175 174 175 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 178 184 178 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 330 343 330 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">longer arrows</italic>
###xml 346 348 346 348 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b </bold>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 403 404 403 404 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 588 599 588 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">long arrows</italic>
###xml 905 917 905 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">small arrows</italic>
###xml 1025 1026 1025 1026 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1033 1034 1033 1034 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1044 1045 1044 1045 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
Morphology of neuronal pentraxin II immunoreactive deposits in the Parkinsonian substantia nigra. a Lewy bodies are labelled which often show a crennelated surface (also see c). Arrows of the inset point to NPTX2 labelled connections/"bridges" between small Lewy bodies. Cross-sectioned axon bundles in white matter are numerous (longer arrows). b Arrows point to Lewy neurites in the substantia nigra. c NPTX2 is present in pre-Lewy bodies and glial cells. Labelling can be seen inside the cytoplasm of nerve cells in the neighbourhood and often directly attached to mature Lewy bodies (long arrows). Note the crenellated surface of compacted NPTX2 deposits (centre and Lewy body at the bottom of the figure) due to hair-like projections, which radiate into the cytoplasm. NPTX2 immunoreactivity is also present in glial cells. A subset of astrocytes as well as possibly microglia appear to be labelled (small arrows). The short arrow in the lower left points to what appears to be nuclear immunoreactivity. Scale bars: 40 (a), 50 (b) and 30 (c) mum, respectively
###end p 31
###begin p 32
Correlation analysis for NPTX2 microarray expression data and the corresponding semi-quantitative immunocytochemical ratings for eight of the PD cases
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 178 181 <span type="species:ncbi:10116">rat</span>
###xml 390 394 <span type="species:ncbi:10090">mice</span>
The most significant finding of this study is the striking presence of NPTX2 in classical Lewy bodies and in Lewy neurites. Experimental studies have demonstrated that Narp, the rat homologue of NPTX2, is important in neuronal development, promoting neuronal migration, synapse formation [1, 8] and neurite outgrowth [31]. Studies in neuronal pentraxin I and neuronal pentraxin II knockout mice have demonstrated a role in early synaptic refinements in the retina and dorsal lateral geniculate nucleus during development [1]. It has also been suggested that Narp's role in synaptic plasticity may underlie the long-lasting aversive effects of drug withdrawal [10, 26]. These functions of the NPTX2 gene product and its dendritic expression in the cerebral cortex [17] are of special interest in relation to our finding that NPTX2 immunoreactivity was also occasionally present in the cortical neuropil where it had a ramified appearance reminiscent of dendritic arbors.
###end p 34
###begin p 35
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 468 469 468 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 522 523 522 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 541 546 541 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink">log&#160;2</sub>
###xml 629 630 629 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 648 653 648 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink">log&#160;2</sub>
###xml 655 656 655 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</sub>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 980 982 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1579 1580 1579 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1695 1701 1695 1701 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 1902 1905 1902 1905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1928 1932 1928 1932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 1979 1983 1979 1983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMPA</italic>
###xml 2042 2047 2042 2047 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA1</italic>
###xml 2088 2093 2088 2093 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA2</italic>
###xml 2134 2139 2134 2139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA3</italic>
###xml 2181 2186 2181 2186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA4</italic>
###xml 2228 2233 2228 2233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTX1</italic>
###xml 2256 2261 2256 2261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTX2</italic>
###xml 2285 2290 2285 2290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTXR</italic>
###xml 2320 2330 2320 2330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Green line</italic>
###xml 2344 2355 2344 2355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">purple line</italic>
###xml 2370 2387 2370 2387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted grey lines</italic>
###xml 2426 2437 2426 2437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid lines</italic>
###xml 2465 2476 2465 2476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">grey colour</italic>
###xml 1701 2635 1701 2635 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36">NPTX2 pathway obtained by means of the Resnet 5.0 eukaryotic database of molecular interactions (Ariadne) overlayed with microarray expression values. Changes of PD relative to normal are indicated in <italic>red</italic> (increased in PD) and <italic>blue</italic> (downregulated), respectively. Abbreviations: <italic>AMPA</italic> alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; <italic>GRIA1</italic> glutamate receptor, ionotropic, AMPA 1; <italic>GRIA2</italic> glutamate receptor, ionotropic, AMPA 2; <italic>GRIA3</italic> glutamate receptor, ionotrophic, AMPA 3; <italic>GRIA4</italic> glutamate receptor, ionotrophic, AMPA 4; <italic>NPTX1</italic> neuronal pentraxin I; <italic>NPTX2</italic> neuronal pentraxin II; <italic>NPTXR</italic> neuronal pentraxin receptor. <italic>Green line</italic>, regulation; <italic>purple line</italic>, binding. The <italic>dotted grey lines</italic> connect to a cell process whereas the <italic>solid lines</italic> connect to a molecule. The <italic>grey colour</italic> indicates that the effect and/or mechanism are unknown. References for all protein interactions shown are provided in the Electronic Supplement to this figure</p>
###xml 1701 2635 1701 2635 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36">NPTX2 pathway obtained by means of the Resnet 5.0 eukaryotic database of molecular interactions (Ariadne) overlayed with microarray expression values. Changes of PD relative to normal are indicated in <italic>red</italic> (increased in PD) and <italic>blue</italic> (downregulated), respectively. Abbreviations: <italic>AMPA</italic> alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; <italic>GRIA1</italic> glutamate receptor, ionotropic, AMPA 1; <italic>GRIA2</italic> glutamate receptor, ionotropic, AMPA 2; <italic>GRIA3</italic> glutamate receptor, ionotrophic, AMPA 3; <italic>GRIA4</italic> glutamate receptor, ionotrophic, AMPA 4; <italic>NPTX1</italic> neuronal pentraxin I; <italic>NPTX2</italic> neuronal pentraxin II; <italic>NPTXR</italic> neuronal pentraxin receptor. <italic>Green line</italic>, regulation; <italic>purple line</italic>, binding. The <italic>dotted grey lines</italic> connect to a cell process whereas the <italic>solid lines</italic> connect to a molecule. The <italic>grey colour</italic> indicates that the effect and/or mechanism are unknown. References for all protein interactions shown are provided in the Electronic Supplement to this figure</p></caption>
###xml 2635 2635 2635 2635 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2007_309_Fig4_HTML" id="MO5"/>
###xml 1695 2635 1695 2635 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="36">NPTX2 pathway obtained by means of the Resnet 5.0 eukaryotic database of molecular interactions (Ariadne) overlayed with microarray expression values. Changes of PD relative to normal are indicated in <italic>red</italic> (increased in PD) and <italic>blue</italic> (downregulated), respectively. Abbreviations: <italic>AMPA</italic> alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; <italic>GRIA1</italic> glutamate receptor, ionotropic, AMPA 1; <italic>GRIA2</italic> glutamate receptor, ionotropic, AMPA 2; <italic>GRIA3</italic> glutamate receptor, ionotrophic, AMPA 3; <italic>GRIA4</italic> glutamate receptor, ionotrophic, AMPA 4; <italic>NPTX1</italic> neuronal pentraxin I; <italic>NPTX2</italic> neuronal pentraxin II; <italic>NPTXR</italic> neuronal pentraxin receptor. <italic>Green line</italic>, regulation; <italic>purple line</italic>, binding. The <italic>dotted grey lines</italic> connect to a cell process whereas the <italic>solid lines</italic> connect to a molecule. The <italic>grey colour</italic> indicates that the effect and/or mechanism are unknown. References for all protein interactions shown are provided in the Electronic Supplement to this figure</p></caption><graphic position="anchor" xlink:href="401_2007_309_Fig4_HTML" id="MO5"/></fig>
There is limited knowledge on the NPTX2 pathway (Fig. 4). Known physiological functions of NPTX2 include a role in the induction of AMPA receptor clustering [7]. NPTX2, NPTX1 and the GRIA3 subunit of AMPA receptors are all upregulated in our dataset. All other AMPA subunits and the receptor for NPTX2, NPTXR are downregulated. Two additional genes whose functions may be associated with AMPA receptors in dopaminergic neurons are also highly dysregulated in PD, NSF (N-ethylmaleimide sensitive fusion protein; 202395_at, P = 1.18252E-05, DElog 2 = -1.389396766) and Calcyon (dopamine receptor D1 interacting protein, 219896_at, P = 4.12902E-06, DElog 2 = -2.049585553). NSF binds the AMPA receptor GluR2 subunit and acts to disrupt GluR2-PICK1 interactions [28]; it may play a role in AMPA receptor trafficking and stabilization. Calcyon is co-expressed in a number of D1 dopamine receptor-positive neurons in brain and, like D1 dopamine receptors, is found in dendritic spines [16]. We also found NPTX2 in glial cells possibly including microglia. However, staining of glia was only present in a subpopulation of cells while neuronal cell processes appeared to be consistently labelled. Why exactly NPTX2 accumulates in Lewy bodies remains unclear at present. However, it is conceivable that NPTX2 is involved in the uptake of synaptic material. Synaptic dysfunction in PD is very significant as suggested by our microarray experiments (unpublished data). The presence of NPTX2 in only a subset of Lewy bodies and its association with their "crenellated surface" shown in Fig. 3 as well as NPTX2 immunoreactive "bridges" between Lewy bodies might indicate a role of NPTX2 in Lewy body growth. Fig. 4NPTX2 pathway obtained by means of the Resnet 5.0 eukaryotic database of molecular interactions (Ariadne) overlayed with microarray expression values. Changes of PD relative to normal are indicated in red (increased in PD) and blue (downregulated), respectively. Abbreviations: AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; GRIA1 glutamate receptor, ionotropic, AMPA 1; GRIA2 glutamate receptor, ionotropic, AMPA 2; GRIA3 glutamate receptor, ionotrophic, AMPA 3; GRIA4 glutamate receptor, ionotrophic, AMPA 4; NPTX1 neuronal pentraxin I; NPTX2 neuronal pentraxin II; NPTXR neuronal pentraxin receptor. Green line, regulation; purple line, binding. The dotted grey lines connect to a cell process whereas the solid lines connect to a molecule. The grey colour indicates that the effect and/or mechanism are unknown. References for all protein interactions shown are provided in the Electronic Supplement to this figure
###end p 35
###begin p 36
###xml 201 204 201 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 227 231 227 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AMPA</italic>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA1</italic>
###xml 387 392 387 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA2</italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA3</italic>
###xml 480 485 480 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRIA4</italic>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTX1</italic>
###xml 555 560 555 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTX2</italic>
###xml 584 589 584 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NPTXR</italic>
###xml 619 629 619 629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Green line</italic>
###xml 643 654 643 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">purple line</italic>
###xml 669 686 669 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dotted grey lines</italic>
###xml 725 736 725 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid lines</italic>
###xml 764 775 764 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">grey colour</italic>
NPTX2 pathway obtained by means of the Resnet 5.0 eukaryotic database of molecular interactions (Ariadne) overlayed with microarray expression values. Changes of PD relative to normal are indicated in red (increased in PD) and blue (downregulated), respectively. Abbreviations: AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; GRIA1 glutamate receptor, ionotropic, AMPA 1; GRIA2 glutamate receptor, ionotropic, AMPA 2; GRIA3 glutamate receptor, ionotrophic, AMPA 3; GRIA4 glutamate receptor, ionotrophic, AMPA 4; NPTX1 neuronal pentraxin I; NPTX2 neuronal pentraxin II; NPTXR neuronal pentraxin receptor. Green line, regulation; purple line, binding. The dotted grey lines connect to a cell process whereas the solid lines connect to a molecule. The grey colour indicates that the effect and/or mechanism are unknown. References for all protein interactions shown are provided in the Electronic Supplement to this figure
###end p 36
###begin p 37
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 8 16 <span type="species:ncbi:9606">patients</span>
###xml 591 594 <span type="species:ncbi:10116">rat</span>
Many PD patients also show non-motor symptoms such as hallucinations, depression, autonomic dysfunction and sleep-disturbances. All these symptoms are present in narcolepsy where there is loss of orexin (hypocretin) producing nerve cells in the hypothalamus [2, 30]. It is noteworthy therefore that the same population of neurons shows massive cell loss in PD as shown recently [9, 30]. In addition, Thannickal et al. observed a significant correlation with the clinical stage of PD [30]. It is intriguing that orexin neurons of the hypothalamus demonstrate robust expression of Narp in the rat [27].
###end p 37
###begin p 38
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 1067 1068 1067 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 226 231 <span type="species:ncbi:9606">human</span>
The relationship between NPTX2 and cell death deserves further study. All subunits of the NMDA, AMPA and kainate classes of glutamate receptors and a set of NMDA receptor-associated intracellular proteins are expressed in the human substantia nigra pars compacta, and may play a role in glutamate regulation of dopaminergic activity and/or release [21]. AMPA in turn has been discovered to be a mediator of selective non-apoptotic cell death in dopaminergic neurons [4]. The latter differs ultrastructurally from both neuronal apoptosis and typical excitotoxicity. Importantly, this mode of cell death is independent of caspase activity and does not have the morphological appearance of classical apoptosis. The findings are thus in keeping with our old postulate that nigral neurons are likely to die of a mechanism other than classical apoptosis and that aposklesis ("withering") may be a more appropriate term [12, 13]. The involvement of NPTX2 in cell death mechanisms is additionally supported by studies on the effect of ceramide, which activates TNF-pathways [4]. Therefore, NPTX2/Narp has to be considered a new important gene in PD dysregulation which may be linked to both motor dysfunction caused by nigral dopaminergic nerve cell death in the midbrain and dementia due to synaptic changes in the cerebral cortex.
###end p 38
###begin title 39
Electronic supplementary material
###end title 39
###begin p 40
Below is the link to the electronic supplementary material.
###end p 40
###begin p 41
Supplemental Figure 1. Cluster analysis is a method to organize genes in a microarray dataset into groups (clusters) of similar expression values. We have used ArrayAssist 5.5 software (Stratagene) to produce this image which shows that NPTX2 is not the only gene that is significantly up-regulated in the Parkinsonian substantia nigra compared to control and whose expression varies within the cohort. The latter is important because unlike a number of other highly dysregulated genes which show greater similarity across cases and therefore higher p values, NPTX2 fits better with both the clinical and neuromorphological notion of different disease stages in different cases. There was a good correlation between expression values and immunocytochemical results (Table 1). Abbreviations: CON, control; LN, lateral nigra; MN medial nigra; PD, Parkinson's disease. Codes CON10, CON2, CON3, CON9, PDC1, PD01- PD36 relate to study cases 19, 17, 18, 23, 16, 1-15, respectively (Supplemental Table). The colour range of expression values represents a logarithmic scale. The correlation of expression between different cases, or the distance between rows, i.e. their similarity measure, was determined as follows: a hierarchical clustering algorithm was applied with "Pearson centred" as the distance function, the "centroid" linkage rule was used, and clustering was performed on the whole nigral transcriptome. (JPG 3.35 mb)
###end p 41
###begin p 42
Supplement to Fig. 4 (PDF 85.7 kb)
###end p 42
###begin p 43
Supplemental Table 1. Cases used in the study (PDF 37.8 kb)
###end p 43
###begin p 44
We are most grateful to the brain donors and their relatives for providing tissue to the UK Parkinson's Disease Society Tissue Bank, funded by the Parkinson's disease Society of the UK, registered charity 948776. We would like to thank Maurice R. Elphick for provision of the microscope and colour camera for photography of the in situ hybridization material. We would also like to thank the donors of the UK Multiple Sclerosis Society Tissue Bank.
###end p 44
###begin title 45
References
###end title 45
###begin article-title 46
Neuronal pentraxins mediate synaptic refinement in the developing visual system
###end article-title 46
###begin article-title 47
###xml 23 28 <span type="species:ncbi:9606">human</span>
Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy
###end article-title 47
###begin article-title 48
Concomitant loss of dynorphin, NARP, and orexin in narcolepsy
###end article-title 48
###begin article-title 49
Ultrastructural characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced cell death in embryonic dopaminergic neurons
###end article-title 49
###begin article-title 50
Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson's disease
###end article-title 50
###begin article-title 51
The Narp hypothesis?
###end article-title 51
###begin article-title 52
Seeking long-term relationship: axon and target communicate to organize synaptic differentiation
###end article-title 52
###begin article-title 53
Hypocretin (orexin) loss in Parkinson's disease
###end article-title 53
###begin article-title 54
###xml 67 70 <span type="species:ncbi:10116">rat</span>
Effects of acute administration of methamphetamine on Narp mRNA in rat brain
###end article-title 54
###begin article-title 55
Long pentraxins: an emerging group of proteins with diverse functions
###end article-title 55
###begin article-title 56
Nigral neurons are likely to die of a mechanism other than classical apoptosis in Parkinson's disease
###end article-title 56
###begin article-title 57
Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts
###end article-title 57
###begin article-title 58
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization
###end article-title 58
###begin article-title 59
Biochemical interactions of the neuronal pentraxins. Neuronal pentraxin (NP) receptor binds to taipoxin and taipoxin-associated calcium-binding protein 49 via NP1 and NP2
###end article-title 59
###begin article-title 60
Retraction
###end article-title 60
###begin article-title 61
Cellular and molecular mechanisms of dendrite growth
###end article-title 61
###begin article-title 62
Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord
###end article-title 62
###begin article-title 63
Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease
###end article-title 63
###begin article-title 64
Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra
###end article-title 64
###begin article-title 65
Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia
###end article-title 65
###begin article-title 66
Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp
###end article-title 66
###begin article-title 67
Synaptically targeted narp plays an essential role in the aggregation of AMPA receptors at excitatory synapses in cultured spinal neurons
###end article-title 67
###begin article-title 68
Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
###end article-title 68
###begin article-title 69
Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis
###end article-title 69
###begin article-title 70
Opiate withdrawal induces Narp in the extended amygdale
###end article-title 70
###begin article-title 71
Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons
###end article-title 71
###begin article-title 72
N-ethylmaleimide-sensitive factor is required for the synaptic incorporation and removal of AMPA receptors during cerebellar long-term depression
###end article-title 72
###begin article-title 73
###xml 75 78 <span type="species:ncbi:10116">rat</span>
Identification of the sites of expression of triple A syndrome mRNA in the rat using in situ hybridisation
###end article-title 73
###begin article-title 74
Hypocretin (orexin) cell loss in Parkinson's disease
###end article-title 74
###begin article-title 75
Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity
###end article-title 75
###begin article-title 76
Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity
###end article-title 76
###begin p 77
This work was supported by the Parkinson's Disease Society of the UK.
###end p 77
###begin p 78
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 78
###begin p 79
The online version of this article (doi:10.1007/s00401-007-0309-3) contains supplementary material, which is available to authorized users.
###end p 79

